
LogicBio Therapeutics LOGC
LogicBio Therapeutics Total Assets | LOGC
Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.Main categories of assets
Current assets (used within one year):
- Cash and cash equivalents
- Accounts receivable (amounts owed by customers)
- Inventory of goods, raw materials, and supplies
- Short-term investments
- Fixed assets (buildings, machinery, equipment)
- Intangible assets (brands, patents, software)
- Long-term investments
- Goodwill (reputational value from mergers)
Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.
Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.
Annual Total Assets LogicBio Therapeutics
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 62.8 M | 80.6 M | 55.7 M | 82.9 M | 26.2 M | 2.03 M | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 82.9 M | 2.03 M | 51.7 M |
Quarterly Total Assets LogicBio Therapeutics
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 38.6 M | 47 M | 51.9 M | 62.8 M | 68.2 M | 77.9 M | 73.9 M | 80.6 M | 41.8 M | 47.3 M | 48.7 M | 55.7 M | 67.1 M | 68 M | 76.6 M | 82.9 M | 17 M | 82.9 M | 82.9 M | 26.2 M | 26.2 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 82.9 M | 17 M | 58.3 M |
Total Assets of other stocks in the Biotechnology industry
| Issuer | Total Assets | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MannKind Corporation
MNKD
|
792 M | $ 3.85 | -2.66 % | $ 1.18 B | ||
|
Dyadic International
DYAI
|
9.95 M | $ 0.29 | -6.53 % | $ 10.5 M | ||
|
Merck & Co.
MRK
|
137 B | $ 133.34 | 0.4 % | $ 334 B | ||
|
Moderna
MRNA
|
12.3 B | $ 195.25 | -2.05 % | $ 76 B | ||
|
NuCana plc
NCNA
|
29.8 M | $ 0.75 | 4.39 % | $ 8.42 B | ||
|
Novartis AG
NVS
|
111 B | $ 150.51 | -0.47 % | $ 292 B | ||
|
Puma Biotechnology
PBYI
|
216 M | $ 7.05 | -1.05 % | $ 353 M | ||
|
Fulcrum Therapeutics
FULC
|
324 M | $ 3.69 | -0.67 % | $ 281 M | ||
|
PDS Biotechnology Corporation
PDSB
|
30.5 M | $ 0.79 | -2.58 % | $ 36.6 M | ||
|
Geron Corporation
GERN
|
571 M | $ 0.87 | -4.76 % | $ 580 M | ||
|
Pharming Group N.V.
PHAR
|
341 M | $ 11.54 | -5.18 % | $ 7.95 B | ||
|
Phathom Pharmaceuticals
PHAT
|
259 M | $ 4.65 | -8.46 % | $ 339 M | ||
|
Genmab A/S
GMAB
|
45.8 B | $ 50.36 | -1.93 % | $ 3.26 B | ||
|
Gossamer Bio
GOSS
|
172 M | $ 10.69 | -4.81 % | $ 2.44 B | ||
|
Grifols, S.A.
GRFS
|
21.4 B | $ 8.14 | -0.73 % | $ 5.53 B | ||
|
Liquidia Corporation
LQDA
|
328 M | $ 54.39 | -3.96 % | $ 4.68 B | ||
|
GlaxoSmithKline plc
GSK
|
61.1 B | $ 47.8 | -0.05 % | $ 194 B | ||
|
MediciNova
MNOV
|
45.6 M | $ 1.3 | 2.36 % | $ 63.8 M | ||
|
PTC Therapeutics
PTCT
|
2.9 B | $ 56.23 | -3.59 % | $ 4.47 B | ||
|
Pulmatrix
PULM
|
4.5 M | $ 1.24 | -12.34 % | $ 4.53 B | ||
|
InflaRx N.V.
IFRX
|
55.2 M | $ 1.05 | -3.67 % | $ 70.7 M | ||
|
Immunome
IMNM
|
683 M | $ 15.69 | -5.54 % | $ 1.37 B | ||
|
Immuron Limited
IMRN
|
10.1 M | $ 0.9 | 5.87 % | $ 208 M | ||
|
Incyte Corporation
INCY
|
6.96 B | $ 114.5 | -1.19 % | $ 22.4 B | ||
|
INmune Bio
INMB
|
32.4 M | $ 0.82 | -8.41 % | $ 20.3 M | ||
|
Dr. Reddy's Laboratories Limited
RDY
|
493 B | $ 14.88 | 0.24 % | $ 12.4 B | ||
|
Regeneron Pharmaceuticals
REGN
|
40.6 B | $ 920.38 | -0.22 % | $ 96.3 B | ||
|
Ionis Pharmaceuticals
IONS
|
3.52 B | $ 26.58 | -2.37 % | $ 4.25 B | ||
|
Enlivex Therapeutics Ltd.
ENLV
|
2.33 B | $ 1.06 | -10.92 % | $ 48.4 M | ||
|
Ironwood Pharmaceuticals
IRWD
|
397 M | $ 4.68 | -0.53 % | $ 757 M | ||
|
Kala Pharmaceuticals
KALA
|
9.49 M | $ 2.73 | -9.61 % | $ 22.2 M | ||
|
Intellia Therapeutics
NTLA
|
842 M | $ 10.02 | 5.24 % | $ 1.09 B | ||
|
Adagene
ADAG
|
78.3 M | $ 1.8 | -10.56 % | $ 106 M | ||
|
Denali Therapeutics
DNLI
|
1.14 B | $ 18.43 | 1.29 % | $ 3.18 B | ||
|
Pfizer
PFE
|
208 B | $ 27.4 | -0.62 % | $ 156 B | ||
|
Amarin Corporation plc
AMRN
|
671 M | $ 10.56 | -6.26 % | $ 4.38 B | ||
|
ImmuCell Corporation
ICCC
|
42.5 M | $ 11.08 | -0.81 % | $ 100 M | ||
|
Editas Medicine
EDIT
|
187 M | $ 1.63 | -4.68 % | $ 145 M | ||
|
Kiniksa Pharmaceuticals, Ltd.
KNSA
|
764 M | $ 93.83 | 0.32 % | $ 6.96 B | ||
|
Agios Pharmaceuticals
AGIO
|
1.3 B | $ 27.54 | -4.24 % | $ 1.6 B | ||
|
Royalty Pharma plc
RPRX
|
19.6 B | $ 68.45 | 1.08 % | $ 29.4 B | ||
|
Equillium
EQ
|
31.9 M | $ 1.06 | -5.36 % | $ 60.7 M | ||
|
Black Diamond Therapeutics
BDTX
|
143 M | $ 1.32 | -5.04 % | $ 75.1 M | ||
|
Abeona Therapeutics
ABEO
|
220 M | $ 2.42 | -1.17 % | $ 128 M | ||
|
ACADIA Pharmaceuticals
ACAD
|
1.56 B | $ 17.1 | -2.79 % | $ 2.88 B | ||
|
Atossa Therapeutics
ATOS
|
47.6 M | $ 1.6 | -8.86 % | $ 13.8 M | ||
|
Cleveland BioLabs, Inc.
CBLI
|
2.32 M | - | -7.31 % | $ 49 M | ||
|
Rhythm Pharmaceuticals
RYTM
|
480 M | $ 112.31 | -3.84 % | $ 7.3 B | ||
|
Five Prime Therapeutics, Inc.
FPRX
|
332 M | - | - | $ 1.77 B | ||
|
ADC Therapeutics SA
ADCT
|
323 M | $ 1.29 | -2.28 % | $ 164 M |